Go Deep
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,010 | -10.5 | 1.13 | 0.02 | 1,636.11 |
| Oct 2026 | 21,019 | -10.4 | 1.13 | 0.02 | 1,626.45 |
| Oct 2026 | 20,985 | -10.6 | 1.14 | 0.02 | 1,644.73 |
| Oct 2026 | 21,127 | -10.1 | 1.09 | 0.02 | 1,563.74 |
| Oct 2026 | 21,087 | -10.2 | 1.10 | 0.02 | 1,587.23 |
| Oct 2026 | 21,006 | -10.5 | 1.13 | 0.02 | 1,630.84 |
| Oct 2026 | 21,054 | -10.3 | 1.11 | 0.02 | 1,601.28 |
| Oct 2026 | 21,031 | -10.4 | 1.12 | 0.02 | 1,610.31 |
Janux Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 10,267,000.0 | 3,733,000.0 | 0.0 | 10,000,000.0 |
| Net Profit | -21,972,000.0 | -24,361,000.0 | -31,946,000.0 | -24,313,000.0 |
| EPS | -0.3 | -0.4 | -0.5 | -0.4 |
Janux Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 10,000,000.0 | 10,588,000.0 | 8,083,000.0 | 8,612,000.0 | — |
| Net Profit | -113,625,000.0 | -68,994,000.0 | -58,293,000.0 | -63,059,000.0 | — |
| EPS | -1.8 | -1.3 | -1.3 | -1.5 | — |
Janux Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,001,565,000.0 | 1,061,516,000.0 | 380,407,000.0 | 364,010,000.0 | — |
| Total Liabilities | 44,743,000.0 | 38,735,000.0 | 36,058,000.0 | 43,270,000.0 | — |
| Total Equity | 956,822,000.0 | 1,022,781,000.0 | 344,349,000.0 | 320,740,000.0 | — |
Owes vs Owns
Janux Therapeutics, Inc. owed $0.08 for every $1 it owned in Jun 2026, down from $0.12 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.08× | 0.04× | 0.04× | 0.09× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Janux Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 96.5%Receivables 0.6%Fixed assets (tangible) 2.2%Other assets 0.6%
How it's funded — Dec 2025
Long-term debt 2.0%Other liabilities 1.8%Shareholders' equity 95.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 966.6 | 1,025.2 | 344.0 | 327.0 |
| Receivables | 6.4 | 5.4 | 2.2 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 22.3 | 24.1 | 27.8 | 29.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.3 | 6.8 | 6.4 | 7.6 |
| Liabilities & equity | ||||
| Short-term debt | 2.4 | 1.7 | 1.5 | 0.8 |
| Long-term debt | 19.7 | 21.3 | 23.0 | 24.5 |
| Payables | 5.0 | 4.0 | 2.4 | 2.2 |
| Other liabilities | 17.6 | 11.7 | 9.1 | 15.8 |
| Shareholders' equity | 956.8 | 1,022.8 | 344.3 | 320.7 |
| Net tangible assets | 956.8 | 1,022.8 | 344.3 | 320.7 |
Janux Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -82,235,000.0 | -43,814,000.0 | -50,575,000.0 | -42,922,000.0 | — |
| Investing Activities | -300,981,000.0 | -258,021,000.0 | -41,194,000.0 | 58,266,000.0 | — |
| Financing Activities | 4,945,000.0 | 713,235,000.0 | 59,548,000.0 | 500,000.0 | — |